Procaps Group S.A. Warrants
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.099
- Today's High:
- $0.117
- Open Price:
- $0.115
- 52W Low:
- $0.05
- 52W High:
- $0.9298
- Prev. Close:
- $0.1224
- Volume:
- 0
Company Statistics
- Market Cap.:
- $0
- Book Value:
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- 0%
- Return on Equity TTM:
- 0%
Company Profile
Procaps Group S.A. Warrants had its IPO on 2021-09-30 under the ticker symbol PROCW.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Procaps Group S.A. Warrants has a staff strength of 0 employees.
Stock update
Shares of Procaps Group S.A. Warrants opened at $0.12 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.1 - $0.12, and closed at $0.11.
This is a -6.13% slip from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of Procaps Group S.A. Warrants have slipped by -13.35%.
Procaps Group S.A. Warrants's Key Ratios
Procaps Group S.A. Warrants has a market cap of $0, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Procaps Group S.A. Warrants’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Procaps Group S.A. Warrants's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Procaps Group S.A. Warrants’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.
In Q1, Procaps Group S.A. Warrants’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Procaps Group S.A. Warrants’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Procaps Group S.A. Warrants’s profitability.
Procaps Group S.A. Warrants stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Procaps Group S.A. Warrants stock pays annual dividends of $ per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $490.72 million
- Total Liabilities
- $243.88 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $7.86 million
- Dividend Payout Ratio
- 0%
Procaps Group S.A. Warrants ended 2024 with $490.72 million in total assets and $0 in total liabilities. Its intangible assets were valued at $490.72 million while shareholder equity stood at $32.96 million.
Procaps Group S.A. Warrants ended 2024 with $0 in deferred long-term liabilities, $243.88 million in other current liabilities, 1011000.00 in common stock, $-362432000.00 in retained earnings and $5.79 million in goodwill. Its cash balance stood at $11.54 million and cash and short-term investments were $19.97 million. The company’s total short-term debt was $118,684,000 while long-term debt stood at $169.64 million.
Procaps Group S.A. Warrants’s total current assets stands at $295.55 million while long-term investments were $8.19 million and short-term investments were $8.43 million. Its net receivables were $169.59 million compared to accounts payable of $85.97 million and inventory worth $103.48 million.
In 2024, Procaps Group S.A. Warrants's operating cash flow was $0 while its capital expenditure stood at $7.86 million.
Comparatively, Procaps Group S.A. Warrants paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.11
- 52-Week High
- $0.9298
- 52-Week Low
- $0.05
- Analyst Target Price
- $
Procaps Group S.A. Warrants stock is currently trading at $0.11 per share. It touched a 52-week high of $0.9298 and a 52-week low of $0.9298. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.11 and 200-day moving average was $0.4 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Procaps Group S.A. Warrants
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Procaps Group, S.A. operates as an integrated healthcare and pharmaceutical company worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately ten therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg City, Luxembourg.